Advertisement

Topics

Incysus Therapeutics’ Scientific Co-Founder Lawrence Lamb, Ph.D. and Marcela Maus, M.D., Ph.D. to Co-Chair Gene Therapy Symposium During 2018 ASGCT Meeting

20:00 EDT 16 May 2018 | Globe Newswire

Symposium Title: “Tipping Point: Gene Therapy Entering the Market”

Bruce Levine, Ph.D. to Present: “Regulatory and Technical Lessons Learned in Transfer of Gene Therapy Products from Academia to Industry”

NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, announced today that Lawrence S. Lamb, Ph.D., Professor of Medicine and Director of the Cell Therapy Laboratory at the University of Alabama at Birmingham (UAB) and Scientific Co-Founder of Incysus, and Marcela V. Maus, M.D., Ph.D., Director of Cellular Immunotherapy at the Massachusetts General Hospital Cancer Center in Boston, and a founding member of the Incysus Scientific Advisory Board (SAB), will co-chair a scientific symposium during the 21st Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), in Chicago, Illinois. 

The symposium, titled, “Tipping Point: Gene Therapy Entering the Market” has been organized by the Clinical Trials and Regulatory Affairs Committee of ASGCT and will include Bruce L. Levine, Ph.D. the Barbara and Edward Netter Professor in Cancer Gene Therapy, and Founding Director of the Clinical Cell and Vaccine Production Facility (CVPF) in the Department of Pathology and Laboratory Medicine at the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania.  Dr. Levine is also a founding member of Incysus’ SAB and his presentation is titled, “Regulatory and Technical Lessons Learned in Transfer of Gene Therapy Products from Academia to Industry.”

   Scientific Symposium 300 
   Title:
 Tipping Point: Gene Therapy Entering the Market
    Date and Time:  Friday, May 18, 2018, 8:00 a.m. CT
   Co-Chairs: Lawrence S. Lamb, Ph.D., Marcela V. Maus, M.D., Ph.D.
   Speaker: Bruce L. Levine, Ph.D.
   Presentation: Regulatory and Technical Lessons Learned in Transfer of Gene Therapy Products from Academia to Industry
      

About Incysus Therapeutics, Inc.
Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, our technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers. Incysus’ immuno-oncology programs include activated and gene-modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. For more information, visit www.incysus.com.

Contact:
Incysus Therapeutics, Inc.
(646) 820-8474
info@incysus.com

Primary Logo

NEXT ARTICLE

More From BioPortfolio on "Incysus Therapeutics’ Scientific Co-Founder Lawrence Lamb, Ph.D. and Marcela Maus, M.D., Ph.D. to Co-Chair Gene Therapy Symposium During 2018 ASGCT Meeting"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...